Publication:
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

dc.contributor.authorOzaras, Resat
dc.contributor.authorMete, Bilgul
dc.contributor.authorCeylan, Bahadir
dc.contributor.authorOzgunes, Nail
dc.contributor.authorGunduz, Alper
dc.contributor.authorKaraosmanoglu, Hayat
dc.contributor.authorCagatay, Atahan
dc.contributor.authorGokturk, Kadir
dc.contributor.authorErdem, Levent
dc.contributor.authorKocak, Funda
dc.contributor.authorSenates, Ebubekir
dc.contributor.authorTABAK, Ömer Fehmi
dc.date.accessioned2020-10-22T19:24:02Z
dc.date.available2020-10-22T19:24:02Z
dc.date.issued2014-07-01T00:00:00Z
dc.description.abstractBackground Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.
dc.identifier.citationOzaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., Cagatay A., Gokturk K., Erdem L., Kocak F., et al., -First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment-, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, ss.774-780, 2014
dc.identifier.doi10.1097/meg.0000000000000099
dc.identifier.pubmed24901822
dc.identifier.scopus84902131297
dc.identifier.urihttp://hdl.handle.net/20.500.12645/24438
dc.identifier.wosWOS:000337151300013
dc.titleFirst-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment
dc.typeArticle
dspace.entity.typePublication
local.avesis.idb5694265-a766-4a54-b9b1-c3f4b6b168e6
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files